MR成像引导策略在活检初治男性前列腺癌检测中的成本效益
该决策分析模型针对因直肠指检异常或前列腺特异性抗原升高而首次推荐前列腺活检的活检初治男性(41-50、51-60、61-70岁),评估标准经直肠超声引导活检与多种MR成像引导活检策略的成本效益。结果显示,非增强MR成像后认知引导MR活检(MR阴性时不做标准活检)最具成本效益,较标准活检增加0.198 QALY的净健康获益;非增强MR成像后机架内MR引导活检增加净健康获益最高,为0.251 QALY;所有MR策略在94.05%的蒙特卡洛模拟中具成本效益。
要点
- 非增强MR成像后认知引导MR活检(MR阴性时不做标准活检)较标准活检增加0.198 QALY净健康获益。
- 非增强MR成像后机架内MR引导活检(MR阴性时不做标准活检)净健康获益最高,较标准活检增加0.251 QALY。
- 所有MR成像策略在94.05%的蒙特卡洛模拟中具成本效益,各年龄组分析结果相似。
核心结论
- 在决策分析模型中,MR成像引导策略用于前列腺癌检测较标准活检策略具成本效益。
研究设计与样本
- 决策分析模型,针对因直肠指检异常或前列腺特异性抗原升高而首次推荐前列腺活检的活检初治男性,年龄分组为41-50岁、51-60岁和61-70岁;模型参数来源于文献;支付意愿阈值为每获得1 QALY 50 000美元;采用蒙特卡洛模拟进行概率敏感性分析。
诊断标准与关键数值
- 主要结局指标为净健康获益(NHB),以QALY衡量;非增强MR成像后认知引导MR活检(MR阴性时不做标准活检)较标准活检增加0.198 QALY;非增强MR成像后机架内MR引导活检(MR阴性时不做标准活检)较标准活检增加0.251 QALY;所有MR策略在94.05%的蒙特卡洛模拟中具成本效益。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To evaluate the cost-effectiveness of multiparametric diagnostic magnetic resonance (MR) imaging examination followed by MR imaging-guided biopsy strategies in the detection of prostate cancer in biopsy-naive men presenting with clinical suspicion of cancer for the first time. Materials and Methods A decision-analysis model was created for biopsy-naive men who had been recommended for prostate biopsy on the basis of abnormal digital rectal examination results or elevated prostate-specific antigen levels (age groups: 41-50 years, 51-60 years, and 61-70 years). The following three major strategies were evaluated: (a) standard transrectal ultrasonography (US)-guided biopsy; (b) diagnostic MR imaging followed by MR imaging-targeted biopsy, with no biopsy performed if MR imaging findings were negative; and (c) diagnostic MR imaging followed by MR imaging-targeted biopsy, with a standard biopsy performed when MR imaging findings were negative. The following three MR imaging-guided biopsy strategies were further evaluated in each MR imaging category: (a) biopsy with cognitive guidance, (b) biopsy with MR imaging/US fusion guidance, and (c) in-gantry MR imaging-guided biopsy. Model parameters were derived from the literature. The primary outcome measure was net health benefit (NHB), which was measured as quality-adjusted life-years (QALYs) gained or lost by investing resources in a new strategy compared with a standard strategy at a willingness-to-pay (WTP) threshold of $50 000 per QALY gained. Probabilistic sensitivity analysis was performed by using Monte Carlo simulations. Results Noncontrast MR imaging followed by cognitively guided MR biopsy (no standard biopsy if MR imaging findings were negative) was the most cost-effective approach, yielding an additional NHB of 0.198 QALY compared with the standard biopsy approach. Noncontrast MR imaging followed by in-gantry MR imaging-guided biopsy (no standard biopsy if MR imaging findings were negative) led to the highest NHB gain of 0.251 additional QALY compared with the standard biopsy strategy. All MR imaging strategies were cost-effective in 94.05% of Monte Carlo simulations. Analysis by age groups yielded similar results. Conclusion MR imaging-guided strategies for the detection of prostate cancer were cost-effective compared with the standard biopsy strategy in a decision-analysis model. © RSNA, 2017 Online supplemental material is available for this article.
引用
- Pahwa S, Schiltz NK, Ponsky LE, et al. Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men. Radiology. 2017. PMID: 28514203. doi:10.1148/radiol.2017162181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。